

1 **Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with**
2 **Moderate to Severe COVID 19: A Phase IIa Trial**

3
4 Jennifer Sasson¹, Alexandra N. Donlan^{1,2}, Jennie Z. Ma³, Heather Haughey⁴, Rachael Coleman¹, Uma
5 Nayak⁵, Amy J. Mathers^{1,6}, Patrick E. H. Jackson¹, Scott K. Heysell¹, Jeffrey M. Sturek⁴, William A. Petri,
6 Jr^{1,2,6*}

7
8 ¹Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health System,
9 Charlottesville, VA, USA;

10 ²Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA, USA;

11 ³Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA;

12 ⁴Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia Health System, Charlottesville,
13 VA, USA;

14 ⁵Center for Public Health Genomics and Department of Public Health Sciences, University of Virginia School of Medicine,
15 Charlottesville, VA, USA;

16 ⁶Department of Pathology, University of Virginia Health System, Charlottesville, VA, USA

17

18 *Corresponding author: William A. Petri Jr. University of Virginia, 345 Crispell Drive, Charlottesville Virginia 22908-1340, USA.

19 Email: wap3g@virginia.edu; Phone: 434.924.5621. ORCID ID 0000-0002-7268-1218

20 **ABSTRACT**

21 Background: A profound need remains to develop further therapeutics for treatment of those
22 hospitalized with COVID-19 to prevent respiratory decline or death. Based on data implicating
23 the type 2 cytokine interleukin (IL)-13 as a significant factor leading to critical COVID-19, this
24 trial was designed to assess the safety and efficacy of dupilumab, a monoclonal antibody that
25 blocks IL-13 and IL-4 signaling, in those hospitalized with COVID-19.

26 Methods: We conducted a phase IIa randomized double-blind placebo-controlled trial to assess
27 the safety and efficacy of dupilumab plus standard of care versus placebo plus standard of care
28 in mitigating respiratory failure and death in those hospitalized with COVID-19. Subjects were
29 followed prospectively for 60 days, with collection of clinical outcomes, adverse events and
30 immunologic biomarkers at multiple time points throughout the study period. The primary
31 endpoint was the proportion of patients alive and free of invasive mechanical ventilation at 28
32 days analyzed in logistic regression.

33 Results: Forty eligible subjects were enrolled from June 23, 2021 through November 11, 2021.
34 There was no difference in adverse events nor in proportion of patients alive and free of
35 mechanical ventilation at day 28 between study treatment groups. However, for the secondary
36 endpoint of mortality at day 60, subjects randomized to dupilumab had a higher survival rate:
37 89.5% of subjects in the dupilumab group were alive compared to 76.2% in the placebo group
38 (adjusted HR 0.05, 95% CI: 0.0- 0.72, p=0.03). There was a trend toward reduction in ICU
39 admission in the dupilumab group compared to the placebo group (33.3% vs 66.7%; adjusted
40 HR 0.44, 95% CI: 0.09-2.09, p=0.30). Lastly, we saw downstream evidence of IL-4 and IL-13
41 signaling blockade through analysis of immune biomarkers at multiple study time points.

42 Conclusions: Dupilumab was well tolerated and improved 60-day survival in patients
43 hospitalized with moderate to severe COVID-19. Blockade of type 2 immunity offers promise as
44 a novel treatment for COVID-19.

45

46 **INTRODUCTION:**

47 With in-hospital mortality of 10-26%^{1,2} and the ongoing threats of new SARS-CoV-2 variants,
48 there remains a substantial need for additional therapeutics for those hospitalized with COVID-
49 19. Current therapies have demonstrated variable and/or modest benefit. For example, the
50 RECOVERY trial showed a mortality reduction from 26% to only 23% with dexamethasone use
51 in those hospitalized with COVID-19 respiratory failure, with the greatest mortality benefit seen
52 in those requiring mechanical ventilation at randomization³. Clinical trials for remdesivir, an
53 antiviral nucleoside analog, have produced variable results, with the ACTT-1 trial demonstrating
54 a 5 day reduction in clinical recovery time in those on supplemental oxygen⁴. Randomized
55 controlled trials investigating interleukin (IL)-6 inhibitors have shown conflicting results, with
56 some indicating a mortality benefit in those within 24 hours of intensive care unit (ICU)
57 admission and others showing no difference in clinical outcomes between study groups^{5,6}.
58 Janus kinase inhibitors initially showed only a 1 day improvement in clinical recovery time when
59 combined with remdesivir, with later trials since showing reduced mortality from 13% to 8%
60 when combined with usual care in those requiring hospitalization and at least 1 elevated
61 inflammatory marker^{7,8}. Findings from these studies suggest a need for improvement in
62 treatment of those admitted with COVID-19 pneumonia.

63
64 We have discovered that COVID-19 patients with high plasma IL-13 levels have a significantly
65 greater risk of needing mechanical ventilation⁹. IL-13, which signals through the receptor IL-4R α
66 along with the closely related cytokine IL-4, is involved in eosinophilic inflammation, mucous
67 secretion, goblet cell metaplasia and fibrosis, and has been regularly implicated in airway
68 hyperresponsiveness and atopic disease¹⁰. We additionally found that neutralization of IL-13 in
69 K18-hACE2 C57Bl/6J mice protected the animals from severe infection with SARS-CoV-2, as
70 evidenced by reduced clinical score, weight loss and mortality⁹. The association of IL-13 along
71 with other effectors of type 2 immunity with respiratory failure from COVID-19 has also been

72 demonstrated in other observation studies^{11,12}. These findings established mechanistic and
73 biologic plausibility for IL-13 as a driver of pulmonary injury in COVID-19.

74

75 There are medications available to block IL-13 signaling: dupilumab, an anti-IL-4R α monoclonal
76 antibody, was approved for treatment of moderate to severe atopic dermatitis by the FDA in
77 2017. It reduces clinical severity in patients with allergic diseases including atopic dermatitis,
78 asthma and chronic rhinosinusitis¹³. The original clinical trials demonstrated minimal adverse
79 events with dupilumab use, favoring it as a steroid sparing therapy in atopic disease^{14,15}. Post
80 hoc analysis of initial studies saw reduced incidence of respiratory viral infections with its use¹⁶.

81

82 Dupilumab use was associated with greater survival from COVID-19 in retrospective analysis:
83 using the TriNetX international electronic medical record (EMR) database, we previously
84 identified a cohort of 350,004 patients with COVID-19, of whom 81 had been prescribed
85 dupilumab prior to their COVID-19 diagnosis⁹. Patients on dupilumab had a 12.3% absolute risk
86 reduction in mortality compared to a propensity score matched sub cohort of 81 patients with
87 COVID-19 not on dupilumab but with atopic diseases for which dupilumab is routinely used⁹.
88 Dupilumab has since been shown to reduce symptom severity and improve clinical outcomes in
89 other observational studies utilizing large patient databases^{17,18}.

90

91 The association of IL-13 with COVID-19 respiratory failure, the demonstration of survival benefit
92 with IL-13 blockade in a mouse model and the retrospective EMR analysis showing reduced
93 COVID-19 mortality in those receiving dupilumab for atopic disease, provided significant
94 evidence for further exploration of dupilumab use for treatment of COVID-19. This along with the
95 safety of dupilumab and the potential for a targeted approach to therapy led to the design of a
96 clinical trial to test its use in those hospitalized with COVID-19.

97

98 **METHODS**

99 **Design**

100 This was a randomized, double-blind, placebo-controlled trial designed to assess the safety and
101 efficacy of dupilumab use in 40 hospitalized patients with moderate to severe COVID-19
102 infection. It was approved by the University of Virginia Institutional Review Board (IRB) in June
103 2021 (NCT04920916). Eligible subjects were enrolled and randomized at a 1:1 ratio to receive
104 either dupilumab or placebo, stratifying on disease severity measured by an oxygen
105 requirement of ≤ 15 L/min or > 15 L/min by nasal cannula. Included were those over the age of
106 18 who were hospitalized with a positive reverse transcription polymerase chain reaction test
107 (RT-PCR) for SARS-CoV-2 within the last 14 days and evidence of moderate to severe COVID-
108 19 as defined by National Institutes of Health (NIH) COVID-19 Severity Categorization¹⁹.
109 Patients requiring mechanical ventilation at the time of enrollment were excluded. Both arms
110 received standard of care management per current NIH COVID-19 treatment guidelines,
111 including dexamethasone and remdesivir as deemed appropriate by their primary provider¹⁹.
112 Subjects received a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous
113 injections) or placebo on day 0 with additional maintenance doses of 300 mg or placebo given
114 on days 14 and 28 if the subject remained hospitalized and receiving active care²⁰. Subjects
115 were followed prospectively for 60 days.

116

117 **Outcomes**

118 The primary outcome of the study was the proportion of patients alive and free of invasive
119 mechanical ventilation at day 28. Safety outcomes were assessed via determination of the
120 cumulative incidence of adverse events, including those previously reported to occur with
121 dupilumab use (i.e., injection site reactions, eye/eyelid inflammation, conjunctivitis, herpes viral
122 infection, eosinophilia)²⁰. Additional clinical endpoints included all-cause mortality at day 28 and
123 60, proportion of patients alive and free of invasive mechanical ventilation at 60 days, hospital

124 length of stay (LOS), ICU LOS, change in 8-point ordinal score and change in partial pressure of
125 oxygen (PaO₂) or oxygen saturation (SaO₂) to fraction of inspired oxygen (FiO₂) ratio. Plasma
126 inflammatory markers, including C reactive protein (CRP), ferritin and a 47-plex cytokine panel
127 were measured at various time points during the study. Additional type 2 inflammatory markers
128 including TARC (CCL17), YKL40, eotaxin 3 (CCL26), arginase1 (Arg1), hyaluronan, soluble
129 ST2 and total serum immunoglobulin E (IgE) were also measured. Ferritin, CRP and IgE levels
130 were measured at the University of Virginia Clinical Laboratories while other biomarkers were
131 measured by multiplex immunoassays or ELISAs depending on the analyte. Day 0
132 nasopharyngeal (NP) swabs obtained for assessment of SARS-CoV-2 RNA positivity via RT-
133 PCR underwent genomic sequencing to determine the SARS-CoV-2 lineage²¹.

134

135 **Statistical Analysis**

136 COVID-19 hospitalization data from UVA between March 2020 and April 2021 showed that
137 79.5% of COVID-19 inpatients were alive and free of mechanical ventilation at 28 days under
138 usual care. With a pre-selected sample size of 40 patients and alpha=0.1 (one sided), we would
139 be able to detect a difference of 17.7% in the proportion of subjects alive and free of mechanical
140 ventilation at 28 days with 75% power.

141

142 Primary and secondary outcomes were analyzed under the intention-to-treat (ITT) principle.
143 Safety outcomes were analyzed in the as treated population, including subjects who were
144 enrolled and received at least one dose of study drug. Demographics, clinical and safety
145 outcomes were analyzed initially with the Chi-square or Fisher's exact tests for categorical
146 measures and two-sample t-test or Wilcoxon rank sum for continuous measures, after
147 assessment of normality. Treatment differences in ventilator free survival proportions were
148 analyzed via logistic regression. Mortality differences were evaluated by the log-rank test and
149 further in the Cox regression for time to death outcome. Baseline patient characteristics and

150 known risk factors for severe disease in COVID-19, including age, sex, body mass index (BMI),
151 comorbidities and COVID-19 vaccination status, were adjusted in regression models if initial
152 analyses discovered imbalance in group characteristics²². Differences in the biomarkers
153 between treatment groups were analyzed exploratively by t-test or Wilcoxon rank sum testing at
154 each time point.

155
156 As an exploratory analysis, we included mechanical ventilation as a time varying variable in the
157 Cox regression for further investigation of its influence on survivability. This allowed us to
158 account for the significant change in mortality risk between pre- and post-intubation when a
159 patient was placed on mechanical ventilation. We additionally tested differences in the likelihood
160 of ICU admission between the two groups by the log-rank test.

161

162 **RESULTS**

163 **Patient and Virus Characteristics**

164 Forty patients were enrolled from June 23, 2021 through November 11, 2021 (Fig S1). The
165 groups were well matched with regard to age, BMI, race, ethnicity, comorbidities, vaccination
166 status and days from COVID-19 symptom onset to enrollment (Table 1). Patients in the placebo
167 arm were more likely to be male compared to the dupilumab arm (76.2% vs. 36.8%). There
168 were no significant differences in non-study COVID-19 therapies received between the
169 treatment groups (Table 1). Of those NP samples available for SARS-CoV-2 sequencing, 30 of
170 31 (96.8%) subjects had the delta variant and one subject in the placebo group had the iota
171 variant (Table S1).

172

173

174

	Placebo (n=21)	Dupilumab (n=19)
Age	63.0 (23.0)	69 (26.0)
Sex		
Male	16 (76.2%)	7 (36.8%)
BMI	32.3 (10.1)	33.6 (14.9)
Ethnicity		
Hispanic	3 (14.3%)	3 (15.8%)
Race		
White	14 (66.7%)	13 (68.4%)
Black	6 (28.6%)	4 (21.1%)
Asian	0 (0.0%)	1 (5.3%)
Other	1 (4.8%)	1 (5.3%)
Comorbidities		
Obesity	15 (71.4%)	14 (73.7%)
Chronic Kidney Disease	7 (33.3%)	3 (15.8%)
Asthma	4 (19.1%)	4 (21.1%)
Respiratory Disease (COPD, emphysema)	3 (14.3%)	2 (10.5%)
Diabetes	8 (38.1%)	7 (36.8%)
Coronary Artery Disease	6 (28.6%)	3 (15.8%)
Cardiac Valvular Disease	3 (14.3%)	2 (10.5%)
Hypertension	10 (47.6%)	8 (42.1%)
Congestive Heart Failure	5 (23.8%)	2 (10.5%)
Cardiac Arrhythmia	4 (19.1%)	1 (5.3%)
Depression or psychotic disorder	3 (14.3%)	8 (42.1%)
Malignancy	4 (19.1%)	3 (15.8%)
Autoimmune disease	2 (9.5%)	2 (10.5%)
Organ or stem cell transplant recipient	3 (14.3%)	1 (5.3%)
Other immune deficiency	1 (4.8%)	0 (0.0%)
Smoking History		
Never	12 (57.1%)	15 (79.0%)
Current	3 (14.3%)	0 (0.0%)
Past	6 (28.6%)	4 (21.1%)
Days from symptom onset to study treatment	8.0 (4.0)	7.0 (5.0)
Received COVID-19 vaccine		
Moderna	4 (19.1%)	1 (5.3%)
Pfizer	5 (23.8%)	4 (21.1%)
J&J	0 (0.0%)	2 (10.5%)
None	12 (57.1%)	12 (63.2%)
Other COVID-19 therapeutics received		
Steroids	20 (95.2%)	19 (100%)
Remdesivir	10 (47.6%)	16 (84.2%)
IL-6 inhibitor	0 (0.0%)	0 (0.0%)
Janus kinase inhibitor	4 (19.1%)	1 (5.3%)
Monoclonal antibodies	3 (14.3%)	2 (10.5%)

Table 1: Patient characteristics. Continuous variables expressed as median (interquartile range). Categorical variables expressed as total n (percentage). Age expressed in years. Body Mass Index (BMI, kg/m²), Chronic Obstructive Pulmonary Disease (COPD), Johnson and Johnson (J&J).

176 **Safety**

177 There were no significant differences in cumulative adverse events observed between the
178 treatment groups (Table 2). In the dupilumab group, five subjects developed asymptomatic
179 eosinophilia compared to one subject in the placebo group (Fisher's exact p=0.09). There were
180 no clinical consequences, including dermatologic, gastrointestinal, pulmonary, cardiac or
181 neurologic, attributed to the peripheral eosinophilia seen in these subjects.

	Placebo (n=21)	Dupilumab (n=19)
Injection site reactions	0 (0.0%)	0 (0.0%)
Conjunctivitis	2 (9.5%)	0 (0.0%)
Bacterial pneumonia	1 (4.8%)	2 (10.5%)
Herpes viral infection	0 (0.0%)	0 (0.0%)
Eosinophilia*	1 (4.8%)	5 (26.3%)
Hyper eosinophilic syndrome	0 (0.0%)	0 (0.0%)
Other infections	2 (9.5%)	4 (21.1%)
Cumulative	6	11

182 **Table 2:** Adverse events observed throughout the study period by treatment group. Other
183 infections included *Clostridioides difficile* infection (1), bacteremia (2), urinary tract
184 infections (2) and oral candidiasis (1). Categorical variables expressed as total n
185 (percentage). Eosinophilia was defined as an absolute eosinophil count >0.6 k/uL at ≥ 1
measurement throughout the study period. *Difference between treatment groups was not
statistically significant with Fischer's exact p=0.09.

186 **Clinical Efficacy**


187 There was no significant difference in the primary endpoint of proportion of patients alive and
188 free of mechanical ventilation at day 28 between the two groups (Table 3). However, by
189 secondary endpoint at 60 days, 89.5% of subjects in the dupilumab group were alive compared
190 to 76.2% for the placebo group as no patients remained on mechanical ventilation by day 60 in
191 either group (Table 3). After adjustment for sex and mechanical ventilation as a time varying
192 predictor, the risk of death over 60-day follow-up period was significantly lower in dupilumab
193 group compared to placebo (Table 3; Fig 1).

194

195


	Placebo (n=21)	Dupilumab (n=19)	OR (95% CI) or HR (95% CI)	P value
Proportion of patients alive and free of mechanical ventilation by day 28	18 (85.7%)	15 (78.9%)	Unadjusted OR: 1.60 (0.31, 8.30)	0.57
			Adjusted OR: 2.45 (0.40, 15.10)	0.34
Proportion of patients alive and free of mechanical ventilation by day 60	16 (76.2%)	17 (89.5%)	Unadjusted OR: 0.38 (0.06, 2.22)	0.28
			Adjusted OR: 0.44 (0.07, 2.96)	0.40
Mortality by day 28	3 (14.3%)	1 (5.3%)	Unadjusted HR: 0.35 (0.04, 3.32)	0.36
			Adjusted HR: 0.06 (0.00, 1.59)	0.09
Mortality by day 60	5 (23.8%)	2 (10.5%)	Unadjusted HR: 0.40 (0.08, 2.05)	0.27
			Adjusted HR: 0.05 (0.00, 0.72)	0.03

196 **Table 3:** Primary and key secondary endpoints by treatment group. Primary endpoint was ventilator free survival by
 197 day 28. Secondary endpoints were ventilator free survival by day 60, mortality by day 60 and mortality by day 28.
 198 Proportions are listed as total n (%). The differences in the ventilator free survival proportions were evaluated using
 logistic regression, adjusted for sex. The differences in mortality risk were evaluated in the Cox regression, adjusted
 for sex and time varying mechanical ventilation.



199 **Figure 1:** Kaplan Meier survival curves depicting 60-day mortality between
 200 two treatment groups. Dupilumab group is represented by blue line. Placebo
 201 group is represented by the orange line. Adjusted p value indicative of
 202 adjustment for sex and time varying ventilation in the Cox regression. Patient
 203 study visits occurred within an allotted range of exact study days and
 therefore the number at risk in the table is representative of patient data
 availability up until those exact days (i.e., if study visit was conducted on day
 59 and no event had occurred, then the subject was included in the at-risk
 pool up until day 59 but not in that for day 60).

204 Numerically fewer subjects in the dupilumab group required ICU care (33.3%) compared to the
205 placebo group (66.7%) though this difference was not statistically significant (log-rank $p=0.23$,
206 HR 0.44, CI: 0.09-2.09, $p=0.30$ adjusted for sex, Fig 2). There was no difference in additional
207 secondary endpoints between the two treatment groups (Table 4, Fig S2, Fig S3).



208
209 **Figure 2:** Kaplan Meier curve depicting need for escalation to ICU over 60-
210 day study period. Patients already admitted to the ICU on day of enrollment
211 ($n=7$) were excluded from analysis. Dupilumab group is represented by
212 blue line. Placebo group is represented by the orange line. Patient study
visits occurred within an allotted range of exact study days and therefore
the number at risk in the table is representative of patient data availability
up until those exact days (i.e., if study visit was conducted on day 59 and
no event had occurred, then the subject was included in the at-risk pool up
until day 59 but not in that for day 60).

213 **Biomarker Analysis**

214 In both treatment groups, CRP, ferritin and IgE levels declined in the first two weeks with no
215 significant difference in the change in measures from day 0 to 14 between groups (Fig S4).

216 When looking at the change in absolute cell counts over time, there was an increase in
217 eosinophils by day 14 in the dupilumab group compared to the placebo group ($p=0.01$ by

218 Wilcoxon rank sum, Fig S5). Analysis of patient cytokine, chemokine and growth factors in
219 serum at various study time points showed a decreased monocyte chemoattractant protein-1
220 (MCP-1) at day 7 in the dupilumab treatment group compared to placebo ($p=0.04$ by Wilcoxon
221 rank sum, Fig S6). By day 14, there was a larger decrease in eotaxin-3 levels in the dupilumab
222 group compared to the placebo ($p=0.08$ by Wilcoxon rank sum, Fig S6). Additionally, there was
223 a trend towards decreased levels of YKL40 in the dupilumab group compared to the placebo by
224 day 14 ($p=0.26$ by Wilcoxon rank sum, Fig S6).

225

226 **DISCUSSION**

227 In this randomized double-blind placebo-controlled trial, although there was no difference
228 between study groups regarding the primary endpoint of 28-day ventilator free survival, the
229 secondary endpoint of increased 60-day survival in the dupilumab group was achieved.

230 Additionally, there were no safety signals seen with dupilumab use.

231

232 The overall mortality of subjects in this study had a trend toward more severe disease. ICU
233 mortality was 20% in the dupilumab group versus 36% in placebo, and ventilator mortality was
234 50% in the dupilumab group compared to 100% in placebo. Severity of illness seen in our study
235 reflected that enrollment occurred during the delta surge and that the majority of those enrolled
236 were unvaccinated, consistent with national data at the time²³. For example, the National
237 Hospital Care Survey (NHCS) data from the US Centers for Disease Control and Prevention
238 (CDC), showed 11.9-13.1% in-hospital mortality in select hospitals throughout the United States
239 during the month of August 2021 with ventilatory mortality rates ranging from 47.9%-74.1%, a
240 time period during which this study enrolled subjects²⁴.

241

242 The detection of survival and mechanical ventilation differences at 60 days rather than at 28
243 days is consistent with reports of immunologic dysfunction from COVID-19 extending out to 8

244 months for mild to moderate COVID-19, with deaths from severe COVID-19 occurring out to 12
245 months^{25,26}. Although the small size of our study limits broad conclusions about the mortality
246 benefit of dupilumab, these findings combined support a late clinical benefit of blockade of a
247 type 2 immune process in COVID-19. The response to dupilumab in asthma is also protracted
248 with improvements in FEV1 first being observed 2 weeks after initiation of treatment²⁷. Thus, the
249 time to clinical effect of dupilumab in the acute COVID-19 setting may have limited our ability to
250 see early clinical differences between the treatment groups. For example, subjects in our study
251 who ultimately required mechanical ventilation did so within the first 8 days of the study, some
252 within 1-2 days of enrollment, during a time in which drug concentration may have been lower,
253 particularly in the context of a rapidly evolving clinical process.

254

255 Although biomarker trends seen in both groups were likely influenced by the steroids that almost
256 all subjects received, we did see a reduction of the Type 2 immune markers YKL40 and eotaxin-
257 3 in the dupilumab arm when compared to the placebo arm, indicative of the IL-4R α blockade
258 with inhibition of downstream mediators of the type 2 immune response. Increased peripheral
259 eosinophil counts in the dupilumab group occurred by day 14, consistent with previous
260 observations of dupilumab use in patients with atopic disease, likely due to decreased
261 eosinophil uptake in tissue^{27,28}. While we did not see IgE decrease at 2 weeks of dupilumab
262 treatment, this is consistent with prior studies showing gradual decline of IgE levels compared to
263 other biomarkers after dupilumab initiation²⁸. Lastly, we saw reduction in MCP-1, a potent
264 chemoattractant molecule of monocytes/macrophages, in the dupilumab group, high levels of
265 which have been associated with COVID-19 disease severity^{29,30}.

266

267 The study had several limitations. These included the lack of achievement of the primary
268 endpoint of proportion of patients alive and free of mechanical ventilation at day 28, and the
269 wide confidence intervals in the survival benefit of dupilumab at day 60. Additional limitations

270 included unequal gender distribution between groups, and a higher-than-expected overall
271 mortality rate.

272
273 The study also had several notable strengths including having as a foundation the preclinical
274 data on the mechanism of disease exacerbation by IL-13 in COVID-19, originality in the study of
275 type 2 immune inhibition, the use of a prospective placebo-controlled randomized and double-
276 blind design, and demonstration of the safety of dupilumab. Importantly, there was evidence for
277 mortality reduction and reduced ICU escalation with dupilumab use as we had predicted from
278 animal models and retrospective human studies, despite sample size limitations. In light of the
279 ongoing need for additional therapies for COVID-19 associated respiratory failure and the
280 modest clinical benefits seen with other anti-viral and immunotherapies currently being used,
281 the results of this study advance dupilumab as a promising treatment option for those
282 hospitalized with COVID-19.

283
284 **COMPETING INTERESTS STATEMENT:** The authors have no competing interests to report.

285
286 **ACKNOWLEDGEMENTS:** We wish to thank the patients who consented to enroll in this study
287 in an effort to help others with COVID-19 and the nursing staff and providers on the COVID-19
288 units for their assistance with the trial. We thank Jennifer White for IRB protocol preparation,
289 Amy Warren and Lori Elder for IRB protocol preparation and IND preparation/submission and
290 the staff at the investigational drug pharmacy at UVA. We'd also like to thank Mary Young and
291 William Petri and the Biorepository and Tissue Research Facility at UVA who collected,
292 organized and analyzed research samples.

293
294

295 **FUNDING STATEMENT:** This work is supported by grants from the Virginia Biosciences Health
296 Research Corporation, by PBM C19, the Henske Family Foundation, and NIH grants R01
297 AI124214, T32 AI007496 (AD), T32 DK072922/ TL1 DK132771 (JS), UL1TR003015
298 and KL2TR003016 (JMS and JZM).

299

300 **WORKS CITED**

- 301 1. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients:
302 systematic review and meta-analysis. *Ann Epidemiol.* 2021;57:14-21.
303 doi:10.1016/j.annepidem.2021.02.012
- 304 2. Gray WK, Navaratnam A V, Day J, et al. Variability in COVID-19 in-hospital mortality
305 rates between national health service trusts and regions in England: A national
306 observational study for the Getting It Right First Time Programme. *EClinicalMedicine.*
307 2021;35:100859. doi:10.1016/j.eclinm.2021.100859
- 308 3. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med.* 2021;384(8):693-
309 704. doi:10.1056/NEJMoa2021436
- 310 4. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 —
311 Final Report. *N Engl J Med.* 2020;383(19):1813-1826. doi:10.1056/NEJMoa2007764
- 312 5. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe
313 Covid-19 Pneumonia. *N Engl J Med.* 2021;384(16):1503-1516.
314 doi:10.1056/NEJMoa2028700
- 315 6. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med.*
316 2021;384(16):1491-1502. doi:10.1056/NEJMoa2100433
- 317 7. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized
318 Adults with Covid-19. *N Engl J Med.* 2021;384(9):795-807. doi:10.1056/nejmoa2031994
- 319 8. Marconi VC, Ramanan A V, de Bono S, et al. Efficacy and safety of baricitinib for the
320 treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-

- 321 blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med.* 2021;19(21):1-
322 12. doi:10.1016/s2213-2600(21)00331-3
- 323 9. Donlan AN, Sutherland TE, Marie C, et al. IL-13 is a driver of COVID-19 severity. *JCI*
324 *Insight.* 2021;6(15). doi:10.1172/jci.insight.150107
- 325 10. Wynn TA. IL-13 effector functions. *Annu Rev Immunol.* 2003;21:425-456.
326 doi:10.1146/annurev.immunol.21.120601.141142
- 327 11. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in
328 severe COVID-19. *Nature.* 2020;584(7821):463-469. doi:10.1038/s41586-020-2588-y
- 329 12. Liang Y, Ge Y, Sun J. IL-33 in COVID-19: friend or foe? *Cell Mol Immunol.*
330 2021;18(6):1602-1604. doi:10.1038/s41423-021-00685-w
- 331 13. Thibodeaux Q, Smith MP, Ly K, Beck K, Liao W, Bhutani T. A review of dupilumab in the
332 treatment of atopic diseases. *Hum Vaccines Immunother.* 2019;15(9):2129-2139.
333 doi:10.1080/21645515.2019.1582403
- 334 14. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with
335 uncontrolled persistent asthma despite use of medium-to-high-dose inhaled
336 corticosteroids plus a long-acting β 2 agonist: a randomised double-blind placebo-
337 controlled pivotal phase 2b dose-ranging trial. *Lancet.* 2016;388(10039):31-44.
338 doi:10.1016/S0140-6736(16)30307-5
- 339 15. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-
340 to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids
341 (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled,
342 phase 3 trial. *Lancet.* 2017;389(10086):2287-2303. doi:10.1016/S0140-6736(17)31191-1
- 343 16. Geng B, Bachert C, Busse WW, et al. Respiratory Infections and Anti-Infective
344 Medication Use From Phase 3 Dupilumab Respiratory Studies. *J Allergy Clin Immunol*
345 *Pract.* 2022;10(3):732-741. doi:10.1016/j.jaip.2021.12.006
- 346 17. Ungar B, Glickman JW, Golant AK, et al. COVID-19 Symptoms Are Attenuated in

- 347 Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. *J Allergy Clin*
348 *Immunol Pract.* 2022;10(1):134-142. doi:10.1016/j.jaip.2021.10.050
- 349 18. Mahroum N, Damiani G, Watad A, et al. Higher rates of COVID-19 but less severe
350 infections reported for patients on Dupilumab: a Big Data analysis of the World Health
351 Organization VigiBase. *Eur Rev Med Pharmacol Sci.* 2021;25(18):5865-5870.
352 doi:10.26355/eurrev_202109_26808
- 353 19. National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment
354 Guidelines. 2020;2019:130. <https://covid19treatmentguidelines.nih.gov>
- 355 20. Food and Drug Administration (FDA). Dupixent package insert. Published online 2020.
356 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf
- 357 21. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-
358 CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol.* 2020;5(11):1403-1407.
359 doi:10.1038/s41564-020-0770-5
- 360 22. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related
361 death using OpenSAFELY. *Nature.* 2020;584(7821):430-436. doi:10.1038/s41586-020-
362 2521-4
- 363 23. Centers for Disease Control and Prevention (CDC). Rates of laboratory-confirmed
364 COVID-19 hospitalizations by vaccination status. [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination)
365 [tracker/#covidnet-hospitalizations-vaccination](https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination)
- 366 24. Center for Disease Control and Prevention (CDC). In-hospital Mortality Among Hospital
367 Confirmed COVID-19 Encounters by Week From Selected Hospitals.
368 <https://www.cdc.gov/nchs/covid19/nhcs/hospital-mortality-by-week.htm>
- 369 25. Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8
370 months following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol.* Published
371 online 2022. doi:10.1038/s41590-021-01113-x
- 372 26. Mainous AG, Rooks BJ, Wu V, Orlando FA. COVID-19 Post-acute Sequelae Among

- 373 Adults: 12 Month Mortality Risk. *Front Med*. 2021;8. doi:10.3389/fmed.2021.778434
- 374 27. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-
375 Dependent Severe Asthma. *N Engl J Med*. 2018;378(26):2475-2485.
376 doi:10.1056/NEJMoa1804093
- 377 28. Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory
378 biomarkers across multiple atopic, allergic diseases. *Clin Exp Allergy*. 2021;51(7):915-
379 931. doi:10.1111/cea.13954
- 380 29. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte Chemoattractant Protein-1
381 (MCP-1): An Overview. *J Interf Cytokine Res*. 2009;29(6):313-326.
382 doi:10.1089/jir.2008.0027
- 383 30. Chen Y, Wang J, Liu C, et al. IP-10 and MCP-1 as biomarkers associated with disease
384 severity of COVID-19. *Mol Med*. 2020;26(1). doi:10.1186/s10020-020-00230-x
385